Cipla, Kemwell ink biosimilars joint venture

Cipla Limited, a global pharmaceutical company, and Kemwell Biopharma Private Limited, a biopharmaceutical contract development and manufacturing organization (CDMO), have reached a joint venture (JV) agreement to develop, manufacture and commercialize biosimilars for global markets. As a result, a JV company will be incorporated, with the goal of entering the respiratory biosimilars market.

Per the agreement, the JV will use Cipla and Kemwell’s complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing and commercialization of biopharma products. Specifically, Cipla’s respiratory know-how combined with Kemwell’s expertise in biologics will speed up bringing these essential products to market, officials contend.

“We are very excited about combining the strengths of Cipla’s expertise in development and commercialization of respiratory products and Kemwell’s biologics capabilities,” says Anurag Bagaria, Kemwell’s chairman and CEO. “Through this JV, we aim to make cost-effective biotherapeutics available to more patients globally.”